Литература

1. Ortega-Sáenz P., Lopez-Barneo J. Physiology of the carotid body: from molecules to disease. Annu. Rev. Physiol. 2020; 82: 127–149. DOI: 10.1146/annurev-physiol-020518-114427
2. Fitzgerald R.S. The carotid body: terrestrial mammals’ most important peripheral neuroreceptor? J. Neurol. Neurophysiol. 2016; 7: 1000407. DOI: 10.4172/2155-9562.1000407
3. Prabhakar N.R., Peng Y.J., Nanduri J. Recent advances in understanding the physiology of hypoxic sensing by the carotid body. F1000Res. 2018; 7: F1000 Faculty Rev-1900. DOI: 10.12688/f1000research.16247
4. Del Rio R. The carotid body and its relevance in pathophysiology. Exp Physiol. 2015; 100 (2): 121–123. DOI: 10.1113/expphysiol.2014.079350
5. Narkiewicz K., Ratcliffe L.E.K., Hart E.C., Briant L.J.B., Chrostowska M., Wolf J. et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl. Sci. 2016; 1 (5): 313–324. DOI: 10.1016/j.jacbts.2016.06.004
6. Marcus N.J., Del Rio R., Schultz E.P., Xia X.-H., Schultz H.D. Carotid body denervation improves autonomic and cardiac function and attenuates disordered breathing in congestive heart failure. J. Physiol. 2014; 592 (2): 391–408. DOI: 10.1113/jphysiol.2013.266221
7. Schultz H.D., Marcus N.J., Del Rio R. Mechanisms of carotid body chemoreflex dysfunction during heart failure. Exp. Physiol. 2015; 100 (2): 124–129. DOI: 10.1113/expphysiol.2014.079517
8. Toledo C., Andrade D.C., Lucero C., Schultz H.D., Marcus N., Retamal M. et al. Contribution of peripheral and central chemoreceptors to sympatho-excitation in heart failure. J. Physiol. 2017; 595 (1): 43–51. DOI: 10.1113/JP272075
9. Trembach N., Zabolotskikh I. Evaluation of breath-holding test in assessment of peripheral chemoreflex sensitivity in patients with chronic heart failure. Open Respir. Med. J. 2017; 11: 67–74. DOI: 10.2174/1874306401711010067
10. Giannoni A., Mirizzi G., Aimo A., Emdin M., Passino C. Peripheral reflex feedbacks in chronic heart failure: is it time for a direct treatment? World J. Cardiol. 2015; 7 (12): 824–828. DOI: 10.4330/wjc.v7.i12.824
11. Keir D.A., Duffin J., Floras, J.S. Measuring peripheral chemoreflex hypersensitivity in heart failure. Front. Physiol. 2020; 11: 595486. DOI: 10.3389/fphys.2020.595486
12. Kataoka Y., Sales A.R.K., Rodrigues A.G., Goes-Santos B.R., Azevedo L.F., Groehs R.V. et al. Abnormal neurovascular control during central and peripheral chemoreceptors stimulation in heart failure patients with preserved ejection fraction. Clin. Auton. Res. 2024; 34 (3): 363–374. DOI: 10.1007/s10286-024-01041-4
13. Tubek S., Niewinski P., Paleczny B., Langner-Hetmanczuk A., Banasiak W., Ponikowski P. Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients. Sci. Rep. 2021; 11 (1): 20823. DOI: 10.1038/s41598-021-99159-2
14. Collins S.É., Phillips D.B., McMurtry M.S., Bryan T.L., Paterson D.I., Wong E. et al. The effect of carotid chemoreceptor inhibition on exercise tolerance in chronic heart failure. Front. Physiol. 2020; 11: 195. DOI: 10.3389/fphys.2020.00195
15. Kulej-Lyko K., Niewinski P., Tubek S., Krawczyk M., Kosmala W., Ponikowski P. Inhibition of peripheral chemoreceptors improves ventilatory efficiency during exercise in heart failure with preserved ejection fraction – a role of tonic activity and acute reflex response. Front. Physiol. 2022; 13: 911636. DOI: 10.3389/fphys.2022.911636
16. Giannoni A., Gentile F., Buoncristiani F., Borrelli C., Sciarrone P., Spiesshoefer J. et al. Chemoreflex and baroreflex sensitivity hold a strong prognostic value in chronic heart failure. JACC Heart Fail. 2022; 10 (9): 662–676. DOI: 10.1016/j.jchf.2022.02.006
17. Giannoni A., Emdin M., Poletti R., Bramanti F., Prontera C., Piepoli M., Passino C. Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-Stokes respiration and arrhythmias. Clin. Sci. (Lond). 2008; 114 (7): 489–497. DOI: 10.1042/CS20070292
18. Chua T.P., Clark A.L., Amadi A.A., Coats A.J. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J. Am. Coll. Cardiol. 1996; 27 (3): 650–657. DOI: 10.1016/0735-1097(95)00523-4
19. Di Vanna A., Braga A.M., Laterza M.C., Ueno L.M., Rondon M.U., Barretto A.C. et al. Blunted muscle vasodilatation during chemoreceptor stimulation in patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 2007; 293 (1): H846–52. DOI: 10.1152/ajpheart.00156.2007
20. Niewinski P. Pathophysiology and potential clinical applications for testing of peripheral chemosensitivity in heart failure. Curr. Heart Fail. Rep. 2014; 11 (2): 126–133. DOI: 10.1007/s11897-014-0188-6
21. Callegaro C.C., Martinez D., Ribeiro P.A., Brod M., Ribeiro J.P. Augmented peripheral chemoreflex in patients with heart failure and inspiratory muscle weakness. Respir. Physiol. Neurobiol. 2010; 171 (1): 31–35. DOI: 10.1016/j.resp.2010.01.009
22. Despas F., Detis N., Dumonteil N., Labrunee M., Bellon B., Franchitto N. et al. Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation. J. Hypertens. 2009; 27 (9): 1849–1854. DOI: 10.1097/HJH.0b013e32832e8d0f
23. Ponikowski P., Chua T.P., Piepoli M., Ondusova D., Webb-Peploe K., Harrington D. et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation. 1997; 96 (8): 2586–2594. DOI: 10.1161/01.cir.96.8.2586
24. Ponikowski P., Chua T.P., Anker S.D., Francis D.P., Doehner W., Banasiak W. et al. Peripheral chemorecep-tor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation. 2001; 104 (5): 544–549. DOI: 10.1161/hc3101.093699
25. Chua T.P., Ponikowski P., Webb-Peploe K., Harrington D., Anker S.D., Piepoli M., Coats A.J. Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur. Heart J. 1997; 18 (3): 480–486. DOI: 10.1093/oxfordjournals.eurheartj.a015269
26. Hennersdorf M.G., Hillebrand S., Perings C., Strauer B.E. Chemoreflexsensitivity in chronic heart failure patients. Eur. J. Heart Fail. 2001; 3 (6): 679–684. DOI: 10.1016/s1388-9842(01)00189-1
27. Edgell H., McMurtry M.S., Haykowsky M.J., Paterson I., Ezekowitz J.A., Dyck J.R., Stickland M.K. Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients. J. Appl. Physiol. (1985). 2015; 118 (7): 839–848. DOI: 10.1152/japplphysiol.00898.2014
28. Chua T.P., Coats A.J. The reproducibility and comparability of tests of the peripheral chemoreflex: comparing the transient hypoxic ventilatory drive test and the single-breath carbon dioxide response test in healthy subjects. Eur. J. Clin. Invest. 1995; 25 (12): 887–892. DOI: 10.1111/j.1365-2362.1995.tb01962.x
29. Ponikowski P., Chua T.P., Piepoli M., Amadi A.A., Harrington D., Webb-Peploe K. et al. Chemoreceptor dependence of very low frequency rhythms in advanced chronic heart failure. Am. J. Physiol. 1997; 272 (1 Pt 2): H438–47. DOI: 10.1152/ajpheart.1997.272.1.H438
30. McСlean P., Phillipson E., Martinez D., Zamel N. Single breath of CO2 as a clinical test of the peripheral chemoreflex. J. Appl. Physiol. 1988; 64 (1): 84–89. DOI: 10.1152/JAPPL.1988.64.1.84
31. Mirizzi G., Giannoni A., Ripoli A., Iudice G., Bramanti F., Emdin M., Passino C. Prediction of the chemoreflex gain by common clinical variables in heart failure. PloS One. 2016; 11 (4): e0153510. DOI: 10.1371/journal.pone.0153510
32. Duffin J. Measuring the respiratory chemoreflexes in humans. Respir. Physiol. Neurobiol. 2011; 177: 71–79. DOI: 10.1016/j.resp.2011.04.009
33. Boulet L., Jamieson A., Day T.A. The effects of prior hyperventilation duration on central chemoreflex responses using the “Duffin” hyperoxic rebreathing test (1092.16). The FASEB Journal. 2014; 28. DOI: 10.1096/FASEBJ.28.1_SUPPLEMENT.1092.16
34. Dahan A., Nieuwenhuijs D., Teppema L. Plasticity of central chemoreceptors: effect of bilateral carotid body resection on central CO2 sensitivity. PLoS Med. 2007; 4 (7): e239. DOI: 10.1371/journal.pmed.0040239
35. Narkiewicz K., Pesek C.A., van de Borne P.J., Kato M., Somers V.K. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation. 1999; 100 (3): 262–267. DOI: 10.1161/01.cir.100.3.262
36. Sun S.Y., Wang W., Zucker I.H., Schultz H.D. Enhanced peripheral chemoreflex function in conscious rabbits with pacing-induced heart failure. J. Appl. Physiol. (1985). 1999; 86 (4): 1264–1272. DOI: 10.1152/jappl.1999.86.4.1264
37. Ciarka A., Cuylits N., Vachiery J.L., Lamotte M., Degaute J.P., Naeije R., van de Borne P. Increased peripheral chemoreceptors sensitivity and exercise ventilation in heart transplant recipients. Circulation. 2006; 113 (2): 252–257. DOI: 10.1161/CIRCULATIONAHA.105.560649
38. Parkes M.J. Breath-holding and its breakpoint. Exp. Physiol. 2006; 91 (1): 1–15. DOI: 10.1113/expphysiol.2005.031625
39. Заболотских И.Б., Баутин А.Е., Григорьев Е.В., Грицан А.И., Лебединский К.М., Потиевская В.И. и др. Периоперационное ведение пациентов с артериальной гипертензией. Методические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии имени А.И. Салтанова. 2024; 3: 7–26. DOI: 10.21320/1818-474X-2024-3-7-26
40. Daly W.J., Bondurant S. Effects of oxygen breathing on the heart rate, blood pressure, and cardiac index of normal men – resting, with reactive hyperemia, and after atropine. J. Clin. Invest. 1962; 41 (1): 126–132. DOI: 10.1172/JCI104454
41. Ponikowski P., Francis D.P., Piepoli M.F., Davies L.C., Chua T.P., Davos C.H. et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation. 2001; 103 (7): 967–972. DOI: 10.1161/01.cir.103.7.967
42. Haque W.A., Boehmer J., Clemson B.S., Leuenberger U.A., Silber D.H., Sinoway L.I. Hemodynamic effects of supplemental oxygen administration in congestive heart failure. J. Am. Coll. Cardiol. 1996; 27 (2): 353–357. DOI: 10.1016/0735-1097(95)00474-2
43. Bascom D.A., Clement I.D., Dorrington K.L., Robbins P.A. Effects of dopamine and domperidone on ventilation during isocapnic hypoxia in humans. Respir. Physiol. 1991; 85 (3): 319–328. DOI: 10.1016/0034-5687(91)90071-p
44. van de Borne P., Oren R., Somers V.K. Dopamine depresses minute ventilation in patients with heart failure. Circulation. 1998; 98 (2): 12 6–131. DOI: 10.1161/01.cir.98.2.126
45. Giannoni A., Emdin M., Bramanti F., Iudice G., Francis D.P., Barsotti A. et al. Combined increased chemosensitivity to hypoxia and hypercapnia as a prognosticator in heart failure. J. Am. Coll. Cardiol. 2009; 53 (21): 1975–1980. DOI: 10.1016/j.jacc.2009.02.030
46. Niewinski P. Carotid body modulation in systolic heart failure from the clinical perspective. J. Physiol. 2017; 595 (1): 53–61. DOI: 10.1113/JP271692
47. Basting T.M., Burke P.G., Kanbar R., Viar K.E., Stornetta D.S., Stornetta R.L., Guyenet P.G. Hypoxia silences retrotrapezoid nucleus respiratory chemoreceptors via alkalosis. J. Neurosci. 2015; 35 (2): 527–543. DOI: 10.1523/JNEUROSCI.2923-14.2015
48. Floras J.S., Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur. Heart J. 2015; 36 (30): 1974–1982. DOI: 10.1093/eurheartj/ehv087
49. Kious K.W., Philipose A., Smith L.J., Kemble J.P., Twohey S.C.E., Savage K. et al. Peripheral chemoreflex modulation of renal hemodynamics and renal tissue PO2 in chronic heart failure with reduced ejection fraction. Front. Physiol. 2022; 13: 955538. DOI: 10.3389/fphys.2022.955538
50. Marcus N.J., Pugge C., Mediratta J., Schiller A.M., Del Rio R., Zucker I.H., Schultz H.D. Exercise training attenuates chemoreflex-mediated reductions of renal blood flow in heart failure. Am. J. Physiol. Heart Circ. Physiol. 2015; 309: H259–H266. DOI: 10.1152/ajpheart.00268.2015
51. Zannad F., Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018; 138 (9): 929–944. DOI: 10.1161/CIRCULATIONAHA.117.028814
52. Costanzo M.R. The cardiorenal syndrome in heart failure. Cardiol. Clin. 2022; 40 (2): 219–235. DOI: 10.1016/j.ccl.2021.12.010
53. Li Y.-L., Xia X.-H., Zheng H., Gao L., Li Y.-F., Liu D. et al. Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Cardiovasc. Res. 2006; 71 (1): 129–138. DOI: 10.1016/j.cardiores.2006.03.017
54. Cundrle I. Jr, Johnson B.D., Rea R.F., Scott C.G., Somers V.K., Olson L.J. Modulation of ventilatory reflex control by cardiac resynchronization therapy. J. Card. Fail. 2015; 21 (5): 367–373. DOI: 10.1016/j.cardfail.2014.12.013
55. Mezzani A., Pistono M., Agostoni P., Giordano A., Gnemmi M., Imparato A. et al. Exercise gas exchange in continuous-flow left ventricular assist device recipients. PLoS One. 2018; 13 (6): e0187112. DOI: 10.1371/journal.pone.0187112
56. Apostolo A., Paolillo S., Contini M., Vignati C., Tarzia V., Campodonico J. et al. Comprehensive effects of left ventricular assist device speed changes on alveolar gas exchange, sleep ventilatory pattern, and exercise performance. J. Heart Lung. Transplant. 2018; 37 (11): 1361–1371. DOI: 10.1016/j.healun.2018.07.005
57. Imadojemu V.A., Mawji Z., Kunselman A., Gray K.S., Hogeman C.S., Leuenberger U.A. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest. 2007; 131 (5): 1406–1413. DOI: 10.1378/chest.06-2580.
58. Spicuzza L., Bernardi L., Balsamo R., Ciancio N., Polosa R, Di Maria G. Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome. Chest. 2006; 130: 774–779. DOI: 10.1378/chest.130.3.774
59. Fontana M., Emdin M., Giannoni A., Iudice G., Baruah R., Passino C. Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. Am. J. Cardiol. 2011; 107 (11): 1675–1680. DOI: 10.1016/j.amjcard.2011.01.060
60. Lorenzi-Filho G., Rankin F., Bies I., Douglas Bradley T. Effects of inhaled carbon dioxide and oxygen on cheyne-stokes respiration in patients with heart failure. Am. J. Respir. Crit. Care Med. 1999; 159 (5 Pt 1): 1490–1498. DOI: 10.1164/ajrccm.159.5.9810040.
61. Giannoni A., Baruah R., Willson K., Mebrate Y., Mayet J., Emdin M. et al. Real-time dynamic carbon dioxide administration: a novel treatment strategy for stabilization of periodic breathing with potential application to central sleep apnea. J. Am. Coll. Cardiol. 2010; 56 (22): 1832–1837. DOI: 10.1016/j.jacc.2010.05.053
62. Del Rio R., Marcus N.J., Schultz H.D. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J. Am. Coll. Cardiol. 2013; 62 (25): 2422–2430. DOI: 10.1016/j.jacc.2013.07.079
63. Tubek S., Niewinski P., Reczuch K., Janczak D., Rucinski A., Paleczny B. et al. Effects of selective carotid body stimulation with adenosine in conscious humans. J. Physiol. 2016; 594 (21): 6225–6240. DOI: 10.1113/JP272109
64. Javaheri S., Parker T.J., Wexler L., Liming J.D., Lindower P., Roselle G.A. Effect of Theophylline on sleep-disordered breathing in heart failure. N. Engl. J. Med. 1996; 335 (8): 562–567. DOI: 10.1056/NEJM 199608223350805
65. Javaheri S., Guerra L. Lung function, hypoxic and hypercapnic ventilatory responses, and respiratory muscle strength in normal subjects taking oral theophylline. Thorax. 1990; 45 (10): 743–747.
66. Yamauchi M., Dostal J., Kimura H., Strohl K.P. Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains. J. Appl. Physiol. 2008; 105 (2): 518–526. DOI: 10.1152/japplphysiol.00069.2008.
67. Taylor N.C., Li A., Nattie E.E. Medullary serotonergic neurones modulate the ventilatory response to hypercapnia, but not hypoxia in conscious rats. J. Physiol. 2005; 566 (Pt 2): 543–557. DOI: 10.1113/jphysiol.2005.083873
68. Zeitler E.P., Abraham W.T. Novel devices in heart failure: BAT, atrial shunts, and phrenic nerve stimulation. JACC Heart Fail. 2020; 8 (4): 251–264. DOI: 10.1016/j.jchf.2019.11.006
69. Heusser K., Thöne A., Lipp A., Menne J., Beige J., Reuter H. et al. Efficacy of electrical baroreflex activation is independent of peripheral chemoreceptor modulation. Hypertension. 2020; 75 (1): 257–264. DOI: 10.1161/HYPERTENSIONAHA.119.13925
70. Victor R.G. Carotid baroreflex activation therapy for resistant hypertension. Nat. Rev. Cardiol. 2015; 12 (8): 451–463. DOI: 10.1038/nrcardio.2015.96
71. Zile M.R., Lindenfeld J., Weaver F.A., Zannad F., Galle E., Rogers T., Abraham W.T. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 2020; 76. DOI: 10.1016/j.jacc.2020.05.015
72. Dell’Oro R., Gronda E., Seravalle G., Costantino G., Alberti L., Baronio B. et al. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report. J. Hypertens. 2017; 35: 2532–2536. DOI: 10.1097/HJH.0000000000001498
73. Трембач Н.В. Влияние чувствительности периферического хеморефлекса на частоту критических инцидентов в течение сочетанной анестезии. Кубанский научный медицинский вестник. 2018; 25 (3): 113–118. DOI: 10.25207/1608-6228-2018-25-3-113-118
74. Trembach N.V. The influence of peripheral chemoreflex sensitivity on the critical incidents rate during combined anesthesia. Kuban Scientific Medical Bulletin. 2018; 25 (3): 113–118 (in Russ.). DOI: 10.25207/1608-6228-2018-25-3-113-118
75. Числова А.П., Юрлов И.А. Влияние хронической гипоксемии и высокой концентрации гемоглобина на развитие осложнений в раннем послеоперационном периоде у больных с врожденными пороками сердца цианотического типа после операций с искусственным кровообращением. Клиническая физиология кровообращения. 2017; 14 (4): 220–225. DOI: 10.24022/1814-6910-2017-14-4-220-225

1. Ortega-Sáenz P., Lopez-Barneo J. Physiology of the carotid body: from molecules to disease. Annu. Rev. Physiol. 2020; 82: 127–149. DOI: 10.1146/annurev-physiol-020518-114427
2. Fitzgerald R.S. The carotid body: terrestrial mammals’ most important peripheral neuroreceptor? J. Neurol. Neurophysiol. 2016; 7: 1000407. DOI: 10.4172/2155-9562.1000407
3. Prabhakar N.R., Peng Y.J., Nanduri J. Recent advances in understanding the physiology of hypoxic sensing by the carotid body. F1000Res. 2018; 7: F1000 Faculty Rev-1900. DOI: 10.12688/f1000research.16247
4. Del Rio R. The carotid body and its relevance in pathophysiology. Exp Physiol. 2015; 100 (2): 121–123. DOI: 10.1113/expphysiol.2014.079350
5. Narkiewicz K., Ratcliffe L.E.K., Hart E.C., Briant L.J.B., Chrostowska M., Wolf J. et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl. Sci. 2016; 1 (5): 313–324. DOI: 10.1016/j.jacbts.2016.06.004
6. Marcus N.J., Del Rio R., Schultz E.P., Xia X.-H., Schultz H.D. Carotid body denervation improves autonomic and cardiac function and attenuates disordered breathing in congestive heart failure. J. Physiol. 2014; 592 (2): 391–408. DOI: 10.1113/jphysiol.2013.266221
7. Schultz H.D., Marcus N.J., Del Rio R. Mechanisms of carotid body chemoreflex dysfunction during heart failure. Exp. Physiol. 2015; 100 (2): 124–129. DOI: 10.1113/expphysiol.2014.079517
8. Toledo C., Andrade D.C., Lucero C., Schultz H.D., Marcus N., Retamal M. et al. Contribution of peripheral and central chemoreceptors to sympatho-excitation in heart failure. J. Physiol. 2017; 595 (1): 43–51. DOI: 10.1113/JP272075
9. Trembach N., Zabolotskikh I. Evaluation of breath-holding test in assessment of peripheral chemoreflex sensitivity in patients with chronic heart failure. Open Respir. Med. J. 2017; 11: 67–74. DOI: 10.2174/1874306401711010067
10. Giannoni A., Mirizzi G., Aimo A., Emdin M., Passino C. Peripheral reflex feedbacks in chronic heart failure: is it time for a direct treatment? World J. Cardiol. 2015; 7 (12): 824–828. DOI: 10.4330/wjc.v7.i12.824
11. Keir D.A., Duffin J., Floras, J.S. Measuring peripheral chemoreflex hypersensitivity in heart failure. Front. Physiol. 2020; 11: 595486. DOI: 10.3389/fphys.2020.595486
12. Kataoka Y., Sales A.R.K., Rodrigues A.G., Goes-Santos B.R., Azevedo L.F., Groehs R.V. et al. Abnormal neurovascular control during central and peripheral chemoreceptors stimulation in heart failure patients with preserved ejection fraction. Clin. Auton. Res. 2024; 34 (3): 363–374. DOI: 10.1007/s10286-024-01041-4
13. Tubek S., Niewinski P., Paleczny B., Langner-Hetmanczuk A., Banasiak W., Ponikowski P. Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients. Sci. Rep. 2021; 11 (1): 20823. DOI: 10.1038/s41598-021-99159-2
14. Collins S.É., Phillips D.B., McMurtry M.S., Bryan T.L., Paterson D.I., Wong E. et al. The effect of carotid chemoreceptor inhibition on exercise tolerance in chronic heart failure. Front. Physiol. 2020; 11: 195. DOI: 10.3389/fphys.2020.00195
15. Kulej-Lyko K., Niewinski P., Tubek S., Krawczyk M., Kosmala W., Ponikowski P. Inhibition of peripheral chemoreceptors improves ventilatory efficiency during exercise in heart failure with preserved ejection fraction – a role of tonic activity and acute reflex response. Front. Physiol. 2022; 13: 911636. DOI: 10.3389/fphys.2022.911636
16. Giannoni A., Gentile F., Buoncristiani F., Borrelli C., Sciarrone P., Spiesshoefer J. et al. Chemoreflex and baroreflex sensitivity hold a strong prognostic value in chronic heart failure. JACC Heart Fail. 2022; 10 (9): 662–676. DOI: 10.1016/j.jchf.2022.02.006
17. Giannoni A., Emdin M., Poletti R., Bramanti F., Prontera C., Piepoli M., Passino C. Clinical significance of chemosensitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-Stokes respiration and arrhythmias. Clin. Sci. (Lond). 2008; 114 (7): 489–497. DOI: 10.1042/CS20070292
18. Chua T.P., Clark A.L., Amadi A.A., Coats A.J. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J. Am. Coll. Cardiol. 1996; 27 (3): 650–657. DOI: 10.1016/0735-1097(95)00523-4
19. Di Vanna A., Braga A.M., Laterza M.C., Ueno L.M., Rondon M.U., Barretto A.C. et al. Blunted muscle vasodilatation during chemoreceptor stimulation in patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 2007; 293 (1): H846–52. DOI: 10.1152/ajpheart.00156.2007
20. Niewinski P. Pathophysiology and potential clinical applications for testing of peripheral chemosensitivity in heart failure. Curr. Heart Fail. Rep. 2014; 11 (2): 126–133. DOI: 10.1007/s11897-014-0188-6
21. Callegaro C.C., Martinez D., Ribeiro P.A., Brod M., Ribeiro J.P. Augmented peripheral chemoreflex in patients with heart failure and inspiratory muscle weakness. Respir. Physiol. Neurobiol. 2010; 171 (1): 31–35. DOI: 10.1016/j.resp.2010.01.009
22. Despas F., Detis N., Dumonteil N., Labrunee M., Bellon B., Franchitto N. et al. Excessive sympathetic activation in heart failure with chronic renal failure: role of chemoreflex activation. J. Hypertens. 2009; 27 (9): 1849–1854. DOI: 10.1097/HJH.0b013e32832e8d0f
23. Ponikowski P., Chua T.P., Piepoli M., Ondusova D., Webb-Peploe K., Harrington D. et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation. 1997; 96 (8): 2586–2594. DOI: 10.1161/01.cir.96.8.2586
24. Ponikowski P., Chua T.P., Anker S.D., Francis D.P., Doehner W., Banasiak W. et al. Peripheral chemorecep-tor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation. 2001; 104 (5): 544–549. DOI: 10.1161/hc3101.093699
25. Chua T.P., Ponikowski P., Webb-Peploe K., Harrington D., Anker S.D., Piepoli M., Coats A.J. Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur. Heart J. 1997; 18 (3): 480–486. DOI: 10.1093/oxfordjournals.eurheartj.a015269
26. Hennersdorf M.G., Hillebrand S., Perings C., Strauer B.E. Chemoreflexsensitivity in chronic heart failure patients. Eur. J. Heart Fail. 2001; 3 (6): 679–684. DOI: 10.1016/s1388-9842(01)00189-1
27. Edgell H., McMurtry M.S., Haykowsky M.J., Paterson I., Ezekowitz J.A., Dyck J.R., Stickland M.K. Peripheral chemoreceptor control of cardiovascular function at rest and during exercise in heart failure patients. J. Appl. Physiol. (1985). 2015; 118 (7): 839–848. DOI: 10.1152/japplphysiol.00898.2014
28. Chua T.P., Coats A.J. The reproducibility and comparability of tests of the peripheral chemoreflex: comparing the transient hypoxic ventilatory drive test and the single-breath carbon dioxide response test in healthy subjects. Eur. J. Clin. Invest. 1995; 25 (12): 887–892. DOI: 10.1111/j.1365-2362.1995.tb01962.x
29. Ponikowski P., Chua T.P., Piepoli M., Amadi A.A., Harrington D., Webb-Peploe K. et al. Chemoreceptor dependence of very low frequency rhythms in advanced chronic heart failure. Am. J. Physiol. 1997; 272 (1 Pt 2): H438–47. DOI: 10.1152/ajpheart.1997.272.1.H438
30. McСlean P., Phillipson E., Martinez D., Zamel N. Single breath of CO2 as a clinical test of the peripheral chemoreflex. J. Appl. Physiol. 1988; 64 (1): 84–89. DOI: 10.1152/JAPPL.1988.64.1.84
31. Mirizzi G., Giannoni A., Ripoli A., Iudice G., Bramanti F., Emdin M., Passino C. Prediction of the chemoreflex gain by common clinical variables in heart failure. PloS One. 2016; 11 (4): e0153510. DOI: 10.1371/journal.pone.0153510
32. Duffin J. Measuring the respiratory chemoreflexes in humans. Respir. Physiol. Neurobiol. 2011; 177: 71–79. DOI: 10.1016/j.resp.2011.04.009
33. Boulet L., Jamieson A., Day T.A. The effects of prior hyperventilation duration on central chemoreflex responses using the “Duffin” hyperoxic rebreathing test (1092.16). The FASEB Journal. 2014; 28. DOI: 10.1096/FASEBJ.28.1_SUPPLEMENT.1092.16
34. Dahan A., Nieuwenhuijs D., Teppema L. Plasticity of central chemoreceptors: effect of bilateral carotid body resection on central CO2 sensitivity. PLoS Med. 2007; 4 (7): e239. DOI: 10.1371/journal.pmed.0040239
35. Narkiewicz K., Pesek C.A., van de Borne P.J., Kato M., Somers V.K. Enhanced sympathetic and ventilatory responses to central chemoreflex activation in heart failure. Circulation. 1999; 100 (3): 262–267. DOI: 10.1161/01.cir.100.3.262
36. Sun S.Y., Wang W., Zucker I.H., Schultz H.D. Enhanced peripheral chemoreflex function in conscious rabbits with pacing-induced heart failure. J. Appl. Physiol. (1985). 1999; 86 (4): 1264–1272. DOI: 10.1152/jappl.1999.86.4.1264
37. Ciarka A., Cuylits N., Vachiery J.L., Lamotte M., Degaute J.P., Naeije R., van de Borne P. Increased peripheral chemoreceptors sensitivity and exercise ventilation in heart transplant recipients. Circulation. 2006; 113 (2): 252–257. DOI: 10.1161/CIRCULATIONAHA.105.560649
38. Parkes M.J. Breath-holding and its breakpoint. Exp. Physiol. 2006; 91 (1): 1–15. DOI: 10.1113/expphysiol.2005.031625
39. Zabolotskikh I.B., Bautin A.E., Grigoryev E.V., Gritsan A.I., Lebedinskii K.M., Potievskaya V.I. et al. Perioperative management of patients with hypertension. Guidelines of the All-Russian Public Organization Federation of Anesthesiologists and Reanimatologists. Annals of Critical Care. 2024; 3: 7–26 (in Russ.). DOI: 10.21320/1818-474X-2024-3-7-26
40. Daly W.J., Bondurant S. Effects of oxygen breathing on the heart rate, blood pressure, and cardiac index of normal men – resting, with reactive hyperemia, and after atropine. J. Clin. Invest. 1962; 41 (1): 126–132. DOI: 10.1172/JCI104454
41. Ponikowski P., Francis D.P., Piepoli M.F., Davies L.C., Chua T.P., Davos C.H. et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation. 2001; 103 (7): 967–972. DOI: 10.1161/01.cir.103.7.967
42. Haque W.A., Boehmer J., Clemson B.S., Leuenberger U.A., Silber D.H., Sinoway L.I. Hemodynamic effects of supplemental oxygen administration in congestive heart failure. J. Am. Coll. Cardiol. 1996; 27 (2): 353–357. DOI: 10.1016/0735-1097(95)00474-2
43. Bascom D.A., Clement I.D., Dorrington K.L., Robbins P.A. Effects of dopamine and domperidone on ventilation during isocapnic hypoxia in humans. Respir. Physiol. 1991; 85 (3): 319–328. DOI: 10.1016/0034-5687(91)90071-p
44. van de Borne P., Oren R., Somers V.K. Dopamine depresses minute ventilation in patients with heart failure. Circulation. 1998; 98 (2): 12 6–131. DOI: 10.1161/01.cir.98.2.126
45. Giannoni A., Emdin M., Bramanti F., Iudice G., Francis D.P., Barsotti A. et al. Combined increased chemosensitivity to hypoxia and hypercapnia as a prognosticator in heart failure. J. Am. Coll. Cardiol. 2009; 53 (21): 1975–1980. DOI: 10.1016/j.jacc.2009.02.030
46. Niewinski P. Carotid body modulation in systolic heart failure from the clinical perspective. J. Physiol. 2017; 595 (1): 53–61. DOI: 10.1113/JP271692
47. Basting T.M., Burke P.G., Kanbar R., Viar K.E., Stornetta D.S., Stornetta R.L., Guyenet P.G. Hypoxia silences retrotrapezoid nucleus respiratory chemoreceptors via alkalosis. J. Neurosci. 2015; 35 (2): 527–543. DOI: 10.1523/JNEUROSCI.2923-14.2015
48. Floras J.S., Ponikowski P. The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. Eur. Heart J. 2015; 36 (30): 1974–1982. DOI: 10.1093/eurheartj/ehv087
49. Kious K.W., Philipose A., Smith L.J., Kemble J.P., Twohey S.C.E., Savage K. et al. Peripheral chemoreflex modulation of renal hemodynamics and renal tissue PO2 in chronic heart failure with reduced ejection fraction. Front. Physiol. 2022; 13: 955538. DOI: 10.3389/fphys.2022.955538
50. Marcus N.J., Pugge C., Mediratta J., Schiller A.M., Del Rio R., Zucker I.H., Schultz H.D. Exercise training attenuates chemoreflex-mediated reductions of renal blood flow in heart failure. Am. J. Physiol. Heart Circ. Physiol. 2015; 309: H259–H266. DOI: 10.1152/ajpheart.00268.2015
51. Zannad F., Rossignol P. Cardiorenal syndrome revisited. Circulation. 2018; 138 (9): 929–944. DOI: 10.1161/CIRCULATIONAHA.117.028814
52. Costanzo M.R. The cardiorenal syndrome in heart failure. Cardiol. Clin. 2022; 40 (2): 219–235. DOI: 10.1016/j.ccl.2021.12.010
53. Li Y.-L., Xia X.-H., Zheng H., Gao L., Li Y.-F., Liu D. et al. Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Cardiovasc. Res. 2006; 71 (1): 129–138. DOI: 10.1016/j.cardiores.2006.03.017
54. Cundrle I. Jr, Johnson B.D., Rea R.F., Scott C.G., Somers V.K., Olson L.J. Modulation of ventilatory reflex control by cardiac resynchronization therapy. J. Card. Fail. 2015; 21 (5): 367–373. DOI: 10.1016/j.cardfail.2014.12.013
55. Mezzani A., Pistono M., Agostoni P., Giordano A., Gnemmi M., Imparato A. et al. Exercise gas exchange in continuous-flow left ventricular assist device recipients. PLoS One. 2018; 13 (6): e0187112. DOI: 10.1371/journal.pone.0187112
56. Apostolo A., Paolillo S., Contini M., Vignati C., Tarzia V., Campodonico J. et al. Comprehensive effects of left ventricular assist device speed changes on alveolar gas exchange, sleep ventilatory pattern, and exercise performance. J. Heart Lung. Transplant. 2018; 37 (11): 1361–1371. DOI: 10.1016/j.healun.2018.07.005
57. Imadojemu V.A., Mawji Z., Kunselman A., Gray K.S., Hogeman C.S., Leuenberger U.A. Sympathetic chemoreflex responses in obstructive sleep apnea and effects of continuous positive airway pressure therapy. Chest. 2007; 131 (5): 1406–1413. DOI: 10.1378/chest.06-2580.
58. Spicuzza L., Bernardi L., Balsamo R., Ciancio N., Polosa R, Di Maria G. Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome. Chest. 2006; 130: 774–779. DOI: 10.1378/chest.130.3.774
59. Fontana M., Emdin M., Giannoni A., Iudice G., Baruah R., Passino C. Effect of acetazolamide on chemosensitivity, Cheyne-Stokes respiration, and response to effort in patients with heart failure. Am. J. Cardiol. 2011; 107 (11): 1675–1680. DOI: 10.1016/j.amjcard.2011.01.060
60. Lorenzi-Filho G., Rankin F., Bies I., Douglas Bradley T. Effects of inhaled carbon dioxide and oxygen on cheyne-stokes respiration in patients with heart failure. Am. J. Respir. Crit. Care Med. 1999; 159 (5 Pt 1): 1490–1498. DOI: 10.1164/ajrccm.159.5.9810040.
61. Giannoni A., Baruah R., Willson K., Mebrate Y., Mayet J., Emdin M. et al. Real-time dynamic carbon dioxide administration: a novel treatment strategy for stabilization of periodic breathing with potential application to central sleep apnea. J. Am. Coll. Cardiol. 2010; 56 (22): 1832–1837. DOI: 10.1016/j.jacc.2010.05.053
62. Del Rio R., Marcus N.J., Schultz H.D. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardiorespiratory function. J. Am. Coll. Cardiol. 2013; 62 (25): 2422–2430. DOI: 10.1016/j.jacc.2013.07.079
63. Tubek S., Niewinski P., Reczuch K., Janczak D., Rucinski A., Paleczny B. et al. Effects of selective carotid body stimulation with adenosine in conscious humans. J. Physiol. 2016; 594 (21): 6225–6240. DOI: 10.1113/JP272109
64. Javaheri S., Parker T.J., Wexler L., Liming J.D., Lindower P., Roselle G.A. Effect of Theophylline on sleep-disordered breathing in heart failure. N. Engl. J. Med. 1996; 335 (8): 562–567. DOI: 10.1056/NEJM 199608223350805
65. Javaheri S., Guerra L. Lung function, hypoxic and hypercapnic ventilatory responses, and respiratory muscle strength in normal subjects taking oral theophylline. Thorax. 1990; 45 (10): 743–747.
66. Yamauchi M., Dostal J., Kimura H., Strohl K.P. Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains. J. Appl. Physiol. 2008; 105 (2): 518–526. DOI: 10.1152/japplphysiol.00069.2008.
67. Taylor N.C., Li A., Nattie E.E. Medullary serotonergic neurones modulate the ventilatory response to hypercapnia, but not hypoxia in conscious rats. J. Physiol. 2005; 566 (Pt 2): 543–557. DOI: 10.1113/jphysiol.2005.083873
68. Zeitler E.P., Abraham W.T. Novel devices in heart failure: BAT, atrial shunts, and phrenic nerve stimulation. JACC Heart Fail. 2020; 8 (4): 251–264. DOI: 10.1016/j.jchf.2019.11.006
69. Heusser K., Thöne A., Lipp A., Menne J., Beige J., Reuter H. et al. Efficacy of electrical baroreflex activation is independent of peripheral chemoreceptor modulation. Hypertension. 2020; 75 (1): 257–264. DOI: 10.1161/HYPERTENSIONAHA.119.13925
70. Victor R.G. Carotid baroreflex activation therapy for resistant hypertension. Nat. Rev. Cardiol. 2015; 12 (8): 451–463. DOI: 10.1038/nrcardio.2015.96
71. Zile M.R., Lindenfeld J., Weaver F.A., Zannad F., Galle E., Rogers T., Abraham W.T. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction. J. Am. Coll. Cardiol. 2020; 76. DOI: 10.1016/j.jacc.2020.05.015
72. Dell’Oro R., Gronda E., Seravalle G., Costantino G., Alberti L., Baronio B. et al. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report. J. Hypertens. 2017; 35: 2532–2536. DOI: 10.1097/HJH.0000000000001498
73. Трембач Н.В. Влияние чувствительности периферического хеморефлекса на частоту критических инцидентов в течение сочетанной анестезии. Кубанский научный медицинский вестник. 2018; 25 (3): 113–118. DOI: 10.25207/1608-6228-2018-25-3-113-118
74. Trembach N.V. The influence of peripheral chemoreflex sensitivity on the critical incidents rate during combined anesthesia. Kuban Scientific Medical Bulletin. 2018; 25 (3): 113–118 (in Russ.). DOI: 10.25207/1608-6228-2018-25-3-113-118
75. Chislova A.P., Yurlov I.A. Influence of chronic hypoxemia and high concentration of hemoglobin on the development of complications in the early postoperative period in patients with cyanotic congenital heart diseases operated with cardiopulmonary bypass. Clinical Physiology of Circulation. 2017; 14 (4): 220–225 (in Russ.). DOI: 10.24022/1814-6910-2017-14-4-220-225

Об авторах

• Трембач Никита Владимирович, д-р мед. наук, доцент кафедры анестезиологии, реаниматологии и трансфузиологии; ORCID
• Трембач Илья Антонович, ассистент кафедры анестезиологии, реаниматологии и трансфузиологии; ORCID
• Заболотских Игорь Борисович, д-р мед. наук, профессор, заведующий кафедрой анестезиологии, реаниматологии и трансфузиологии; ORCID